Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine.
Shytle
R Douglas
RD
Center for Aging and Brain Repair, Department of Neurosurgery, University of South Florida College of Medicine, 12901 Bruce B. Downs Boulevard, Tampa, FL 33613, USA. dshytle@hsc.usf.edu
Silver
Archie A
AA
Sheehan
Kathy H
KH
Sheehan
David V
DV
Sanberg
Paul R
PR
D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000523:psychology; D002648:Child; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000209:etiology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008464:Mecamylamine / Q000494:pharmacology* / Q000627:therapeutic use*; D009474:Neurons / Q000187:drug effects*; D018733:Nicotinic Antagonists / Q000494:pharmacology* / Q000627:therapeutic use*; D011978:Receptors, Nicotinic / Q000187:drug effects*; D005879:Tourette Syndrome / Q000523:psychology
D018733:Nicotinic Antagonists; D011978:Receptors, Nicotinic; D008464:Mecamylamine